Purple Biotech (PPBT) Other financing activities (2017 - 2025)
Purple Biotech (PPBT) posted quarterly Other financing activities of $4.5 million for Q4 2025, down 16.68% year-over-year from $5.4 million in Q4 2024, and down 16.68% quarter-over-quarter from $5.4 million in Q4 2024.
Purple Biotech (PPBT) Other financing activities (2017 - 2025) Analysis & Trends
Purple Biotech (PPBT) has reported Other financing activities for 7 consecutive years, with $4.5 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Other financing activities fell 16.68% year-over-year to $4.5 million; the TTM figure through Dec 2025 stood at $35.6 million (down 5.11% YoY), while the FY2025 annual figure was $8.7 million, up 17.78% from the prior year.
- Other financing activities slipped to $4.5 million in Q4 2025 per PPBT's latest filing, from $5.4 million in the prior quarter.
- Across five years, Other financing activities topped out at $17.8 million in Q1 2022 and bottomed at -$3.1 million in Q3 2021.
- Historically, Other financing activities has averaged $5.7 million across 4 years, with a median of $5.4 million in 2024.
- Annual changes were most pronounced in 2022 — Other financing activities jumped 1383.33% — and 2025, when it declined 16.68%.
- Purple Biotech's Other financing activities stood at $6.4 million in 2021, then grew by 25.06% to $8.0 million in 2022, then slumped by 32.83% to $5.4 million in 2024, then slipped by 16.68% to $4.5 million in 2025.
- Business Quant data shows PPBT's Other financing activities at $4.5 million in Q4 2025, $5.4 million in Q4 2024, and $8.0 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.72 Bn | 77.73 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.93 Bn | 59.75 Bn | 1.37 Bn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.97 Bn | 36.87 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.22 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.59 Bn | 668.28 Mn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - |
| 10 | Purple Biotech | 127.07 | 127.07 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.48 Mn |
| Dec 31, 2025 | 4.48 Mn |
| Dec 31, 2024 | 5.37 Mn |
| Dec 31, 2024 | 5.37 Mn |
| Dec 31, 2022 | 8.00 Mn |
| Dec 31, 2022 | 8.00 Mn |
| Mar 31, 2022 | 17.80 Mn |
| Mar 31, 2022 | 17.80 Mn |
| Dec 31, 2021 | 6.40 Mn |
| Dec 31, 2021 | 6.40 Mn |
| Sep 30, 2021 | -3.15 Mn |
| Sep 30, 2021 | -3.15 Mn |
| Mar 31, 2021 | 1.20 Mn |
| Mar 31, 2021 | 1.20 Mn |
| Dec 31, 2020 | 5.63 Mn |
| Dec 31, 2020 | 5.63 Mn |
| Dec 31, 2019 | 5.01 Mn |
| Dec 31, 2019 | 5.01 Mn |
| Dec 31, 2017 | 1.11 Mn |
| Dec 31, 2017 | 1.11 Mn |